ConcertAI recently appointed Claudio D'Ambrosio, PhD, as the company’s first chief revenue officer. D'Ambrosio has been with ConcertAI since 2020 as the head of the firm's biopharma partnerships and real-world evidence (RWE) software divisions.
ConcertAI develops artificial intelligence (AI) software-as-a-service (SaaS) technology and RWE software for life sciences and healthcare.
In this new role, D'Ambrosio will lead all biopharma partnering programs and multi-year initiatives in clinical development and post-approval studies.
Before his arrival at ConcertAI, D'Ambrosio served as the head of life sciences for Varian Medical Systems' oncology software solutions. He was also chief commercial officer for Noona.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
